1. Home
  2. LABT vs MTNB Comparison

LABT vs MTNB Comparison

Compare LABT & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$0.84

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Logo Matinas Biopharma Holdings Inc.

MTNB

Matinas Biopharma Holdings Inc.

SELL

Current Price

$3.14

Market Cap

2.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LABT
MTNB
Founded
2006
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.6M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
LABT
MTNB
Price
$0.84
$3.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 638.8K
483.2K
Earning Date
11-18-2026
08-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 59.84
EPS
N/A
★ N/A
Revenue
N/A
★ $119,750.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.82
$0.15
52 Week High
$6.85
$3.05

Technical Indicators

Market Signals
Indicator
LABT
MTNB
Relative Strength Index (RSI) 26.61 84.84
Support Level N/A $0.40
Resistance Level $2.13 N/A
Average True Range (ATR) 0.21 0.19
MACD -0.10 0.29
Stochastic Oscillator 1.78 93.32

Price Performance

Historical Comparison
LABT
MTNB

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

About MTNB Matinas Biopharma Holdings Inc.

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.

Share on Social Networks: